Lonza and Engitix strike ADC licence deal targeting ECM biology
Lonza has granted London-based Engitix a single-target licence covering three components of its antibody-drug conjugate technology platform: the SYNtecan E linker-payload system and the complementary GlycoConnect and HydraSpace conjugation technologies. The agreement, announced on 21 July 2026, allows Engitix to apply this toolkit to targets identified through its proprietary human extracellular matrix discovery platform, with programmes initially spanning fibrosis, oncology, and other diseases driven by abnormal tissue remodelling.
Under the financial terms, Lonza is eligible to receive upfront fees, clinical and regulatory milestone payments, commercial milestones, and royalties on net sales. Lonza retains responsibility for manufacturing the proprietary linker-payload components, while Engitix leads all research, development, and eventual commercialisation activities.
The deal
The strategic rationale turns on Engitix's differentiated approach to target identification. Where most ADC developers select targets expressed on tumour cell surfaces, Engitix focuses on proteins within the extracellular matrix itself, the structural scaffold surrounding cells that is heavily remodelled in fibrotic and malignant tissue. The company says this opens up a class of targets that conventional cell-surface approaches cannot easily reach.
Giuseppe Mazza, chief executive and co-founder of Engitix, said the licence provides "a powerful toolkit to develop next-generation ECM-targeted therapeutics with the potential for enhanced efficacy, reduced toxicity and improved therapeutic index." Jan Vertommen, Lonza's vice president of commercial development in advanced synthesis, described the collaboration as aimed at unlocking "new possibilities in targeted therapies."
Lonza's ADC platform is already established in the CDMO market; the Basel-headquartered group reported sales of CHF 6.5 billion in full-year 2025. The company has pursued a licensing model alongside its manufacturing services, allowing biotech partners to access validated conjugation chemistry without having to build proprietary linker-payload capabilities in-house.
Market context
The ADC sector has seen a significant acceleration in deal activity over the past two years, driven by clinical validation from approved agents across HER2-positive breast cancer, urothelial carcinoma, and other solid tumour indications. That commercial momentum has prompted both large pharmaceutical companies and CDMOs to extend their ADC technology platforms through licensing, partnerships, and acquisitions. Lonza's move to licence its suite to earlier-stage biotechs such as Engitix reflects the broadening of the ADC opportunity beyond oncology's traditional cell-surface target set.
Engitix's ECM-focused approach is relatively uncommon in the ADC field, where the dominant paradigm remains receptor or antigen overexpression on tumour cells. If the platform can identify tractable ECM targets with sufficient tumour selectivity, it could address indications, particularly fibrotic diseases, where ADC development has historically been limited by the absence of well-defined surface antigens. The near-term milestones to watch are the identification of a lead programme with a named ECM target and any disclosure of preclinical efficacy or selectivity data, which will be the first external test of whether the combined approach performs as positioned.